scPharmaceuticals Inc
NASDAQ:SCPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
scPharmaceuticals Inc
Cash Equivalents
scPharmaceuticals Inc
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
scPharmaceuticals Inc
NASDAQ:SCPH
|
Cash Equivalents
$40.8m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash Equivalents
$6B
|
CAGR 3-Years
21%
|
CAGR 5-Years
23%
|
CAGR 10-Years
-8%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash Equivalents
$10.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
16%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash Equivalents
$1.1B
|
CAGR 3-Years
40%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-11%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash Equivalents
$14.6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
13%
|
CAGR 10-Years
6%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash Equivalents
$7.3B
|
CAGR 3-Years
52%
|
CAGR 5-Years
15%
|
CAGR 10-Years
7%
|
|
scPharmaceuticals Inc
Glance View
scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. The company is headquartered in Burlington, Massachusetts and currently employs 26 full-time employees. The company went IPO on 2017-11-17. The firm is focused on exploring, developing and commercializing products that expand and advance the outpatient care of acute conditions, including worsening heart failure and bacterial infections requiring outpatient parenteral antimicrobial therapy. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infusor and is under development for treatment of congestion in patients with heart failure who display reduced responsiveness to oral diuretics and do not require hospitalization. Its area of focus is congestion in heart failure and outpatient parenteral antimicrobial therapy (OPAT). Its pipeline programs include FUROSCIX, scCeftriaxone and scCarbapenem. Its FUROSCIX On-Body Infusor is a drug-device combination product consisting of FUROSCIX. The firm's wholly owned subsidiary is scPharmaceuticals Securities Corporation.
See Also
What is scPharmaceuticals Inc's Cash Equivalents?
Cash Equivalents
40.8m
USD
Based on the financial report for Jun 30, 2025, scPharmaceuticals Inc's Cash Equivalents amounts to 40.8m USD.
What is scPharmaceuticals Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
-12%
Over the last year, the Cash Equivalents growth was 6%.
